![Jason Robins](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jason Robins
Directeur Financier/CFO chez
OCULAR THERAPEUTIX, INC.
Profil
Jason Robins is Chief Financial & Accounting Officer at Ocular Therapeutix, Inc. starting in 2026.
Formerly, Mr. Robins was Vice President-Finance at Fusion Pharmaceuticals, Inc. from 2020 to 2024.
Education includes undergraduate studies at Babson College, graduate studies at Harvard Mit Health Sciences & Technology, and an MBA from MIT Sloan School of Management.
Postes actifs de Jason Robins
| Sociétés | Poste | Début |
|---|---|---|
| OCULAR THERAPEUTIX, INC. | Directeur Financier/CFO | 20/01/2026 |
Anciens postes connus de Jason Robins
| Sociétés | Poste | Fin |
|---|---|---|
| FUSN PHAR | Directeur Financier/CFO | 01/12/2024 |
Formation de Jason Robins
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
9
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Ocular Therapeutix, Inc.
 Ocular Therapeutix, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for retinal diseases & conditions of the eye | Health Technology |
Babson College
 Babson College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Mit Health Sciences & Technology
 Harvard Mit Health Sciences & Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MIT Sloan School of Management
 MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fusion Pharmaceuticals, Inc.
 Fusion Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals for the treatment of cancer | Health Technology |
